Orgenesis, a developer, manufacturer and service provider of advanced cell therapies, has entered into a collaboration and licensing agreement with ExcellaBio for certain technologies developed by Sabina Glozman, Ph.D., including an exosome-like membrane nanostructure (Bioxome) and related processes for the production of exosomes/extracellular vesicles (EVs).  Under the agreement, Orgenesis will have the exclusive, worldwide rights to certain commercial applications of the technology arising from the collaboration.
 
“We are excited to collaborate with ExcellaBio and its founder, Dr. Glozman, on this breakthrough platform for the scalable production of exosomes/EVs,” said Vered Caplan, chief executive officer, Orgenesis. “Exosomes have shown significant promise as a novel alternative to whole cell therapies with potentially superior safety, efficacy and storage/manufacturing properties.”
 
Sabina Glozman, director, ExcellaBio, said, “I am honored to partner with Orgenesis, a leader and pioneer in the field of cell therapy. By combining our unique exosome/EV technology with Orgenesis’ expertise within the cell therapy arena, this collaboration has the potential to enhance many lives. We believe our Bioxome technology has very broad potential across a number of indications ranging from liver fibrosis to aesthetic indications, CNS disorders, as well as many other serious medical conditions.”